Medication mistakes — in which the wrong drug or the wrong dose is given to a patient — are among the most common errors in ...

Addressing the distinction between conception and reduction to practice and the requirement for written description in the ...

• Circadian Metabolism: Nightshift workers show 58% higher obesity rates (WHO) ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered ...

Gene therapy stocks like CRISPR Therapeutics and ... A single clinical trial failure might derail the whole thesis, as the technology needs to pass a series of trials to demonstrate efficacy ...

For the clinical assets that are the focus, given the lack of approval and risk inherent to biotech assets that may fail in ... which CRISPR is looking to initiate a clinical trial this year ...

It appears to have worked in 39 of 42 participants in her trial. The beta-thalassemia patients who received Casgevy have had a similar turnaround. In 2023 Casgevy became the first CRISPR treatment ...

The phase 3 HAELO trial for NTLA-2002, an investigational CRISPR-based ... NTLA-2002, developed using CRISPR/Cas9 gene-editing technology, targets the inactivation of the KLKB1 gene, which encodes ...

The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 gene-editing technology in humans to directly correct the genetic mutation that causes the disease. Sickle cell disease is a genetic ...

The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 gene-editing technology in humans to directly correct the genetic mutation that causes the disease. The research involves taking ...

One company is aiming to treat infections with a different strategy: arming tiny viruses called bacteriophages with Crispr ... Results from a small trial published in August suggest the ...